NCT01797419

Safety Study of GS-5806 to Treat Respiratory Syncytial Virus (RSV)

A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Single-Dose Ranging Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GS-5806 in Subjects < 24 Months of Age Hospitalized for Respiratory Syncytial Virus (RSV) Related Respiratory Infection

• Status: Withdrawn
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Gilead Sciences · Industry
• Sex: All
• Age: 1 Hour – 24 Months
• Healthy volunteers: Not accepted

Summary

The purpose of the study is to evaluate the safety, tolerability, and pharmacokinetics of GS-5806 in hospitalized infants with RSV.

Conditions

• Respiratory Syncytial Virus Infections

Interventions

Type	Name	Description
DRUG	GS-5806	Single dose, oral liquid, .5 mL/kg
DRUG	Placebo	Single dose, oral liquid, .5 mL/kg

Timeline

• Start date: 2013-05-01
• Primary completion: 2013-08-01
• Completion: 2013-08-01
• First posted: 2013-02-22
• Last updated: 2013-10-28

Locations

9 sites across 1 country: Australia